Literature DB >> 26197796

Quality of life and functional evaluation in patients with tongue base tumors treated exclusively with transoral robotic surgery: A 1-year follow-up study.

Giuseppe Mercante1, Alessandra Masiello2, Isabella Sperduti3, Giovanni Cristalli2, Raul Pellini2, Giuseppe Spriano2.   

Abstract

BACKGROUND: To evaluate quality-of-life (QoL), swallowing and voice in patients with base of tongue (BOT) tumors treated with transoral robotic surgery (TORS) alone without any adjuvant treatment.
METHODS: The study was a prospective, single-center cohort trial. Swallowing, QoL and voice were evaluated in 13 patients with T1 or T2 oropharyngeal carcinomas of the BOT. Patients underwent evaluation using the following: a dysphagia score (DS); fiberoptic endoscopic evaluation-of-swallowing with the penetration aspiration scale (PAS); the MD Anderson Dysphagia Inventory (MDADI); and the Voice Handicap Index-10 (VHI-10).
RESULTS: Subjective (DS) and objective (PAS) evaluation of swallowing produced mean scores of 1.08, 2.23 and 1.46 before surgery and at 6 and 12 months after surgery, respectively, for both tests. A significant difference was found when comparing DS and PAS data at baseline and 6 months after surgery; while no difference was observed between the baseline and 12 months after surgery. The mean values of the MDADI and VHI scores recorded before surgery, and at 6 and 12 months after surgery did not show any statistical difference.
CONCLUSIONS: Objective swallowing deterioration in the first 6 months after TORS alone for BOT tumors was possible, but complete recovery of deglutition was observed within 12 months. No changes were reported in the patients' self-perceived status of swallowing and voice dysfunction, and related QoL after 1 year.
Copyright © 2015 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Base of tongue; Oropharyngeal cancer; Quality of life; Swallowing; TORS; Trans-oral robotic surgery

Mesh:

Year:  2015        PMID: 26197796     DOI: 10.1016/j.jcms.2015.06.024

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  7 in total

Review 1.  Treatment preferences in human papillomavirus-associated oropharyngeal cancer.

Authors:  Melina J Windon; Gypsyamber D'Souza; Carole Fakhry
Journal:  Future Oncol       Date:  2018-09-28       Impact factor: 3.404

2.  Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in "Low-Intermediate Risk" Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy.

Authors:  Ryan P Goepfert; Jan S Lewin; Martha P Barrow; G Brandon Gunn; C David Fuller; Beth M Beadle; Adam S Garden; David I Rosenthal; Merrill S Kies; Vassiliki Papadimitrakopoulou; Stephen Y Lai; Neil D Gross; David L Schwartz; Katherine A Hutcheson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-15       Impact factor: 7.038

3.  Transoral robotic surgery vs open surgery in head and neck cancer. A systematic review of the literature.

Authors:  À Roselló; R Albuquerque; X Roselló-Llabrés; A Marí-Roig; A Estrugo-Devesa; J López-López
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2020-09-01

4.  Health related quality of life following the treatment of oropharyngeal cancer by transoral laser.

Authors:  S N Rogers; R S Pinto; J Lancaster; F Bekiroglu; D Lowe; S Tandon; T M Jones
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-18       Impact factor: 2.503

Review 5.  Transoral robotic surgery and intensity-modulated radiotherapy in the treatment of the oropharyngeal carcinoma: a systematic review and meta-analysis.

Authors:  Armando De Virgilio; Andrea Costantino; Giuseppe Mercante; Raul Pellini; Fabio Ferreli; Luca Malvezzi; Giovanni Colombo; Giovanni Cugini; Gerardo Petruzzi; Giuseppe Spriano
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-07-21       Impact factor: 2.503

6.  Morbidity, mortality and cost from HPV-related oropharyngeal cancer: Impact of 2-, 4- and 9-valent vaccines.

Authors:  Greg Ward; Vikas Mehta; Michael Moore
Journal:  Hum Vaccin Immunother       Date:  2015-11-13       Impact factor: 3.452

7.  [Functional results after soft palate reconstruction in oropharyngeal cancer patients].

Authors:  M Herzog; D Grafmans; S K Plontke; S Bartel; S Plößl
Journal:  HNO       Date:  2021-02       Impact factor: 1.284

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.